Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-BIND Validation Study for Depression Biomarkers
NCT04162522Phase 3Completed
- Sponsor
- University Health Network
- Start
- Dec 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of brexpiprazole in major depressive disorder (MDD) (2 arms), sponsored by University Health Network. Primary endpoint: Montgomery Asberg Depression Rating Scale at 16 weeks. Started Dec 2019; status: completed.
02
Drugs
brexpiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04162522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04162522.